Studies on the exacerbation of pulmonary inflammation by viral infection
Based on their previous experience and range of models of asthma, Prof. Broadley, Dr Ford and Dr Kidd have been awarded a contract for £63000 from RespiVert Ltd.
RespiVert Ltd. is a small molecule drug discovery company working on the identification of a new generation of inhaled medicines for life-threatening lung diseases including severe asthma, chronic obstructive pulmonary disease (COPD) and cystic fibrosis.
Aims of Project
To study the exacerbation of pulmonary inflammation by viral infection